These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37657817)

  • 1. Prevalence of sleep disorder diagnoses and sleep medication prescriptions in individuals with ADHD across the lifespan: a Swedish nationwide register-based study.
    Ahlberg R; Garcia-Argibay M; Taylor M; Lichtenstein P; D'Onofrio BM; Butwicka A; Hill C; Cortese S; Larsson H; Du Rietz E
    BMJ Ment Health; 2023 Aug; 26(1):. PubMed ID: 37657817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medications for attention-deficit/hyperactivity disorder in individuals with or without coexisting autism spectrum disorder: analysis of data from the Swedish prescribed drug register.
    Johansson V; Sandin S; Chang Z; Taylor MJ; Lichtenstein P; D'Onofrio BM; Larsson H; Hellner C; Halldner L
    J Neurodev Disord; 2020 Dec; 12(1):44. PubMed ID: 33357227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Psychiatric Comorbidity With the Risk of Premature Death Among Children and Adults With Attention-Deficit/Hyperactivity Disorder.
    Sun S; Kuja-Halkola R; Faraone SV; D'Onofrio BM; Dalsgaard S; Chang Z; Larsson H
    JAMA Psychiatry; 2019 Nov; 76(11):1141-1149. PubMed ID: 31389973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of melatonin in Swedish children and adolescents--a register-based study according to age, gender, and medication of ADHD.
    Furster C; Hallerbäck MU
    Eur J Clin Pharmacol; 2015 Jul; 71(7):877-81. PubMed ID: 25995170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study.
    Ricketts EJ; Sturm A; McMakin DL; McGuire JF; Tan PZ; Smalberg FB; McCracken JT; Colwell CS; Piacentini J
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):690-698. PubMed ID: 30388029
    [No Abstract]   [Full Text] [Related]  

  • 6. Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide Longitudinal Cohort Study.
    Chang Z; D'Onofrio BM; Quinn PD; Lichtenstein P; Larsson H
    Biol Psychiatry; 2016 Dec; 80(12):916-922. PubMed ID: 27086545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.
    Dalsgaard S; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):432-9. PubMed ID: 24015896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups.
    Chung W; Jiang SF; Paksarian D; Nikolaidis A; Castellanos FX; Merikangas KR; Milham MP
    JAMA Netw Open; 2019 Nov; 2(11):e1914344. PubMed ID: 31675080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention-Deficit/Hyperactivity Disorder Diagnoses in Finland During the COVID-19 Pandemic.
    Auro K; Holopainen I; Perola M; Havulinna AS; Raevuori A
    JAMA Netw Open; 2024 Jun; 7(6):e2418204. PubMed ID: 38935377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases.
    Brikell I; Yao H; Li L; Astrup A; Gao L; Gillies MB; Xie T; Zhang-James Y; Dalsgaard S; Engeland A; Faraone SV; Haavik J; Hartman C; Ip P; Jakobsdóttir Smári U; Larsson H; Man KK; de Oliveira Costa J; Pearson SA; Hostrup Nielsen NP; Snieder H; Wimberley T; Wong IC; Zhang L; Zoega H; Klungsøyr K; Chang Z
    Lancet Psychiatry; 2024 Jan; 11(1):16-26. PubMed ID: 38035876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy.
    Brikell I; Chen Q; Kuja-Halkola R; D'Onofrio BM; Wiggs KK; Lichtenstein P; Almqvist C; Quinn PD; Chang Z; Larsson H
    Epilepsia; 2019 Feb; 60(2):284-293. PubMed ID: 30682219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sleep problems and disorders among adolescents with persistent and subthreshold attention-deficit/hyperactivity disorders.
    Gau SS; Chiang HL
    Sleep; 2009 May; 32(5):671-9. PubMed ID: 19480234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study.
    Du Rietz E; Brikell I; Butwicka A; Leone M; Chang Z; Cortese S; D'Onofrio BM; Hartman CA; Lichtenstein P; Faraone SV; Kuja-Halkola R; Larsson H
    Lancet Psychiatry; 2021 Sep; 8(9):774-783. PubMed ID: 34242595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High prevalence of treatment with ADHD medicines indicates overdiagnosis of ADHD in Iceland].
    Ingimarsson O; Gudbrandsdottir RK; Lauth BAM; Sigurdsson E
    Laeknabladid; 2024 Sep; 110(9):402-410. PubMed ID: 39221778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep problems predict comorbid externalizing behaviors and depression in young adolescents with attention-deficit/hyperactivity disorder.
    Becker SP; Langberg JM; Evans SW
    Eur Child Adolesc Psychiatry; 2015 Aug; 24(8):897-907. PubMed ID: 25359419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases.
    Zhang L; Li L; Andell P; Garcia-Argibay M; Quinn PD; D'Onofrio BM; Brikell I; Kuja-Halkola R; Lichtenstein P; Johnell K; Larsson H; Chang Z
    JAMA Psychiatry; 2024 Feb; 81(2):178-187. PubMed ID: 37991787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports.
    Halldner L; Tillander A; Lundholm C; Boman M; Långström N; Larsson H; Lichtenstein P
    J Child Psychol Psychiatry; 2014 Aug; 55(8):897-904. PubMed ID: 24673585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register.
    Zhang L; Lagerberg T; Chen Q; Ghirardi L; D'Onofrio BM; Larsson H; Viktorin A; Chang Z
    Evid Based Ment Health; 2021 Nov; 24(4):146-152. PubMed ID: 33795353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.
    Bachmann CJ; Philipsen A; Hoffmann F
    Dtsch Arztebl Int; 2017 Mar; 114(9):141-148. PubMed ID: 28351466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention-deficit hyperactivity disorder diagnoses and prescriptions in UK primary care, 2000-2018: population-based cohort study.
    McKechnie DGJ; O'Nions E; Dunsmuir S; Petersen I
    BJPsych Open; 2023 Jul; 9(4):e121. PubMed ID: 37455585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.